Barclays Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Underweight rating on Bristol-Myers Squibb (NYSE:BMY) but raises the price target from $41 to $42.
August 22, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Carter Gould maintains an Underweight rating on Bristol-Myers Squibb but raises the price target from $41 to $42, indicating a slight positive outlook despite the overall negative rating.
The Underweight rating suggests a negative outlook, but the raised price target indicates some positive expectations. This mixed signal may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100